Fig. 4: Anti-tumour responses, in terms of incidences of tumours and adaptive T cell responses are based on crystallinity of COFs.
From: Crystallinity of covalent organic frameworks controls immune responses
a Schema of in vivo tumour study. b Kinetics of tumour growth in vaccine treated mice, n = 10 for COFs with OVA, n = 5 for no treatment and soluble OVA. c–f Mice treated with COF1 with OVA had significantly higher number of Th1, activated Th1, Th17 and activated Th17, in tumours (mean ± s.d, n = 4–5 biological replicate, one-way unpaired ANOVA, Fisher LSD test). g Significantly lower number of Treg in tumours of mice treated with COF1 with OVA as compared to no treatment mice, (mean ± s.d, n = 5 or 4, one-way ANOVA Fisher LSD test). h, i The number of Tc1 cells and activated Tc1 cells in mice treated with COF1 OVA has significantly increased compared to the group that received no treatment, in vivo (mean ± s.d, n = 4–5 biological replicate, one-way ANOVA Fisher LSD test), *p = 0.05–0.01, **p < 0.01, ***p < 0.001.
